**Question:** CA-125 is a tumor marker for which of the following malignancies?

A. Breast cancer
B. Colorectal cancer
C. Ovarian cancer
D. Prostate cancer

**Core Concept:** CA-125 is a glycoprotein that is elevated in the bloodstream when certain types of cancer cells secrete or release it. The tumor marker CA-125 is commonly used to monitor the progression and response to treatment in patients with ovarian cancer.

**Why the Correct Answer is Right:** CA-125 is specifically elevated in the serum of patients with epithelial ovarian cancer (EOC). It is produced by the surface cells of ovarian cancer cells, particularly in cases of serous, mucinous, and endometrioid carcinomas.

**Why Each Wrong Option is Incorrect:**

A. Breast cancer: CA-125 is not specific to breast cancer and can be elevated in patients with other malignancies, autoimmune diseases, or even during menstruation.
B. Colorectal cancer: CA-125 elevation is less common in colorectal cancer compared to ovarian cancer, although it can be elevated in patients with advanced disease.
C. Prostate cancer: CA-125 levels are typically normal in patients with prostate cancer.
D. None of the above (all options): CA-125 is not a reliable tumor marker for prostate, colorectal, or breast cancer, and its elevation is less common in these conditions compared to ovarian cancer.

**Clinical Pearl:**

CA-125 is a valuable tool for monitoring disease progression and response to treatment in patients with epithelial ovarian cancer, as well as other malignancies like fallopian tube and peritoneal carcinomas. However, its specificity and sensitivity are limited in differentiating ovarian cancer from benign gynecological conditions and other clinical scenarios. A combination of CA-125 levels with other tumor markers and imaging studies can improve diagnostic accuracy and guide treatment decisions.

**Correct Answer:** C. Ovarian cancer

In conclusion, CA-125 is a tumor marker associated with ovarian cancer due to its production by the surface cells of ovarian cancer cells. While elevated levels can be observed in other malignancies and benign conditions, its association with ovarian cancer makes it a crucial biomarker for monitoring disease progression and treatment response. However, its use should be combined with other diagnostic tools for optimal accuracy.